Atreca, Inc. Profile Avatar - Palmy Investing

Atreca, Inc.

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and t…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Atreca, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Atreca, Inc. can't present revenue by segment

End of BCEL's Analysis
CIK: 1532346 CUSIP: 04965G109 ISIN: US04965G1094 LEI: - UEI: -
Secondary Listings
BCEL has no secondary listings inside our databases.